Eli Lilly Sues Pharmacies and Peptide Vendors Over Retatrutide

Eli Lilly has launched six lawsuits in the U.S. targeting companies, pharmacies, and peptide vendors accused of illegally selling black-market and compounded versions of its experimental obesity drug retatrutide, as consumers increasingly access unapproved versions via medical spas and peptide sellers.

• Eli Lilly filed six lawsuits against U.S. companies.
• The lawsuits target illegal sales of black-market retatrutide.
• Eli Lilly is targeting compounders and peptide vendors over retatrutide.
• Consumers have been using medical spas and peptide sellers to access unapproved versions.